MARKET

AKTX

AKTX

Akari Therapeutics Plc
NASDAQ
1.790
-0.044
-2.38%
Closed 16:00 05/29 EDT
OPEN
1.830
PREV CLOSE
1.834
HIGH
1.835
LOW
1.790
VOLUME
2.67K
TURNOVER
0
52 WEEK HIGH
5.50
52 WEEK LOW
1.078
MARKET CAP
14.18M
P/E (TTM)
-2.1618
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Cue Health stock moved upwards by to $ during Monday's pre-market session. The company's market cap stands at $ billion. Guardant Health shares increased by $ during the session. Losers Verastem and Sensei Biotherapeutics also fell during the pre- market session.
Benzinga · 2d ago
Weekly Report: what happened at AKTX last week (0520-0524)?
Weekly Report · 2d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 5d ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HRT, NX, AKTX
Barchart · 5d ago
Weekly Report: what happened at AKTX last week (0513-0517)?
Weekly Report · 05/20 09:56
Akari Therapeutics GAAP EPS of $0.00
Seeking Alpha · 05/16 13:20
AKARI THERAPEUTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND RECENT HIGHLIGHTS
Reuters · 05/16 12:00
Akari Therapeutics, PLC Quarterly Report for the Period Ending March 31, 2024
Press release · 05/16 08:01
More
About AKTX
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). It is conducting a clinical trial of subcutaneous nomacopan for the treatment of HSCT-TMA in pediatrics. The United States Food and Drug Administration (FDA) has granted Rare Pediatric Disease, Orphan Drug, and Fast Track designations to nomacopan for the treatment of pediatric HSCT-TMA. It is also investigating long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) in preclinical studies.

Webull offers Akari Therapeutics PLC (ADR) stock information, including NASDAQ: AKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKTX stock methods without spending real money on the virtual paper trading platform.